Nanotechnology has been harnessed to kill cancer cells without harming healthy tissue. It works by inserting microscopic synthetic carbon nanotubule rods into cancer cells. When the rods are exposed to near-infra red light from a laser they heat up, killing the cell, while cells without rods are left unharmed.
Standard chemotherapy destroys cancer cells and normal cells alike. That's why patients often lose their hair and suffer numerous other side effects. Researchers look for a way to selectively kill cancer cells and not damage healthy ones."
The researchers believe it should be possible to refine the technique still further, for instance by attaching an antibody to a nanotubule to target a particular kind of cancer cell. They have already started work on tailoring the technique to target lymphoma in mice. This work is still at a very early stage.
Details of the Stanford University work are published by Proceedings of the National Academy of Sciences.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...